- Sections
- C - Chimiemétallurgie
- C12N - Micro-organismes ou enzymescompositions les contenantculture ou conservation de micro-organismestechniques de mutation ou de génétiquemilieux de culture
- C12N 5/16 - Cellules animales
Détention brevets de la classe C12N 5/16
Brevets de cette classe: 1270
Historique des publications depuis 10 ans
|
78
|
85
|
92
|
69
|
61
|
57
|
46
|
39
|
28
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20534 |
16 |
| Regeneron Pharmaceuticals, Inc. | 4593 |
16 |
| F. Hoffmann-La Roche AG | 7835 |
14 |
| Amgen Inc. | 4348 |
13 |
| The Trustees of the University of Pennsylvania | 4403 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2633 |
11 |
| The University of British Columbia | 1529 |
11 |
| Crystal Bioscience Inc. | 85 |
10 |
| Board of Regents, The University of Texas System | 6031 |
9 |
| Abbvie Inc. | 1843 |
9 |
| CRISPR Therapeutics AG | 364 |
9 |
| Genentech, Inc. | 4065 |
8 |
| The Board of Trustees of the Leland Stanford Junior University | 6594 |
8 |
| CHO Plus, Inc. | 16 |
8 |
| Novartis AG | 10346 |
7 |
| The Board of Trustees of the University of Illinois | 2740 |
7 |
| ImmunoGen, Inc. | 383 |
7 |
| Kyoto University | 2887 |
7 |
| Pierre Fabre Medicament | 539 |
7 |
| The Board of Regents of the University of Texas System | 2267 |
7 |
| Autres propriétaires | 1075 |